Literature DB >> 9002062

Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat.

T K McIntosh1, D H Smith, M Voddi, B R Perri, J M Stutzmann.   

Abstract

Several potential mechanisms are involved in mediating the pathophysiology of traumatic brain injury (TBI), including inflammatory processes and excitotoxicity. In the present study, we evaluated the ability of the use-dependent sodium channel inhibitor Riluzole to attenuate cognitive and neurologic motor deficits and reduce regional cerebral edema and histologic cell damage following lateral fluid-percussion (FP) brain injury in rats (n = 109). In study 1, 58 anesthetized male Sprague-Dawley rats (350-400 g) were subjected to FP brain injury of moderate severity (2.3-2.5 atm). Fifteen minutes following brain injury, animals randomly received an i.v. bolus of either Riluzole (4 mg/kg, n = 11), Riluzole (8 mg/kg, n = 11), or glycol vehicle (n = 20), followed by 6 h and 24 h s.c. injections (identical dose). Surgically prepared but uninjured animals received vehicle (n = 16) and served as controls. Animals were evaluated for cognitive deficits at 48 h postinjury and killed for assessment of regional brain edema. Administration of vehicle or Riluzole (4 mg/kg x 3) had no significant effect on memory or edema, whereas Riluzole (8 mg/kg x 3) significantly attenuated post-traumatic cognitive dysfunction (p < 0.05). In study 2, a second group of animals (n = 25) was injured, treated with Riluzole (8 mg/kg x 3 doses, n = 13) or vehicle (n = 12), and evaluated for neurologic motor function over 2 weeks. Animals treated with Riluzole demonstrated significantly improved motor scores beginning 1 week postinjury (p < 0.05). In study 3, brain-injured animals were treated with Riluzole (8 mg/kg x 3 doses, n = 10) or vehicle (n = 10), and posttraumatic lesion volume was assessed at 48 h postinjury using 2,3,5-triphenyltetrazolium chloride (TTC) staining. Treatment with Riluzole had no significant effect on posttraumatic lesion volume. The present study demonstrates that use-dependent sodium channel inhibitors, such as Riluzole, can attenuate both cognitive and neuromotor dysfunction associated with brain trauma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9002062     DOI: 10.1089/neu.1996.13.767

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  15 in total

1.  Blockage of the upregulation of voltage-gated sodium channel nav1.3 improves outcomes after experimental traumatic brain injury.

Authors:  Xian-Jian Huang; Wei-Ping Li; Yong Lin; Jun-Feng Feng; Feng Jia; Qing Mao; Ji-Yao Jiang
Journal:  J Neurotrauma       Date:  2013-12-06       Impact factor: 5.269

2.  Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.

Authors:  Kaleb Yohay; Betty Tyler; Kyle D Weaver; Andrea C Pardo; Dan Gincel; Jaishri Blakeley; Henry Brem; Jeffrey D Rothstein
Journal:  J Neurosurg       Date:  2014-01-31       Impact factor: 5.115

Review 3.  Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications.

Authors:  Fanuel T Hagos; Solomon M Adams; Samuel M Poloyac; Patrick M Kochanek; Christopher M Horvat; Robert S B Clark; Philip E Empey
Journal:  Exp Neurol       Date:  2019-02-21       Impact factor: 5.330

4.  Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study.

Authors:  I Mottet; R Demeure; J Rataud; M Lucas; F Wahl; V Warscotte; J P Thiran; J F Goudemant; B Maldague; J M Maloteaux; J M Stutzmann
Journal:  MAGMA       Date:  1997-09       Impact factor: 2.310

5.  Understanding the role of the primary somatosensory cortex: Opportunities for rehabilitation.

Authors:  M R Borich; S M Brodie; W A Gray; S Ionta; L A Boyd
Journal:  Neuropsychologia       Date:  2015-07-09       Impact factor: 3.139

Review 6.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 7.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury.

Authors:  Carrie A Keck; Hilaire J Thompson; Asla Pitkänen; David G LeBold; Diego M Morales; Jamie B Plevy; Rishi Puri; Boyu Zhao; Marc Dichter; Tracy K McIntosh
Journal:  Restor Neurol Neurosci       Date:  2007       Impact factor: 2.406

Review 9.  Effects of Female Sex Steroids Administration on Pathophysiologic Mechanisms in Traumatic Brain Injury.

Authors:  Mohammad Khaksari; Zahra Soltani; Nader Shahrokhi
Journal:  Transl Stroke Res       Date:  2017-11-19       Impact factor: 6.829

10.  Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury.

Authors:  Yongchao Wu; Kajana Satkunendrarajah; Yang Teng; Diana S-L Chow; Josef Buttigieg; Michael G Fehlings
Journal:  J Neurotrauma       Date:  2013-03-21       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.